Last reviewed · How we verify
Empagliflozin (Jardiance®)
Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.
Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.
At a glance
| Generic name | Empagliflozin (Jardiance®) |
|---|---|
| Sponsor | University Hospital Tuebingen |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
SGLT2 is responsible for reabsorbing filtered glucose in the proximal tubule of the nephron. By blocking this transporter, empagliflozin allows glucose to be excreted in the urine, thereby lowering blood glucose levels independently of insulin secretion. This mechanism also promotes modest osmotic diuresis and has cardiovascular and renal protective effects beyond glycemic control.
Approved indications
- Type 2 diabetes mellitus
- Heart failure with reduced ejection fraction
- Chronic kidney disease
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Diabetic ketoacidosis
- Volume depletion / hypotension
Key clinical trials
- Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)
- Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease
- A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) (PHASE3)
- Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions (NA)
- Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension (PHASE4)
- Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes (PHASE2)
- Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial (PHASE4)
- JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Empagliflozin (Jardiance®) CI brief — competitive landscape report
- Empagliflozin (Jardiance®) updates RSS · CI watch RSS
- University Hospital Tuebingen portfolio CI